Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Vertex Pharmaceuticals

Vertex Pharmaceuticals?uq=3Oe4kK1Z
1989 FOUNDED
PUBLIC STATUS
1K-5K EMPLOYEES
VRTX STOCK SYMBOL
8 INVESTMENTS
$173.78 SHARE PRICE (As of Monday Closing)
Description

Developer of medicines intended to cure diseases and improve people's lives. The company's medicines offer protease inhibitor and new class of antiviral treatments enabling people to transform their lives, families and society.

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 50 Northern Avenue
  • Boston, MA 02210
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Vertex Pharmaceuticals’s full profile, request a free trial.

Vertex Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$140.91 - $192.74 $45.9B $172.21 $2.55 1.4M 256M

Vertex Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Sep-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 47,110,258 36,687,131 18,151,289 30,962,524
Revenue 2,829,125 2,488,652 1,702,177 1,032,336
EBITDA 792,105 103,258 75,464 (411,251)
Net Income 647,053 263,484 (112,052) (556,334)
Total Assets 4,620,840 3,546,014 2,896,787 2,498,587
Total Debt 588,041 606,433 840,761 826,238
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vertex Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Vertex Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Vertex Pharmaceuticals Investments & Acquisitions (8)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 30-Aug-2018 00000 00000 00 000.00 Other Healthcare Technology Systems 00000 000000000 00.0
0000000 0000000000 25-Jul-2017 000000000 00000 00 00000 Other Healthcare Services 0000000 000000 00
0000000 0000000000 07-Sep-2016 00000 00000 00 00000 Drug Discovery
000000 00000000000 13-Jun-2016 00000 00000 00 00000 Pharmaceuticals 00000 000000000 00.0
Avatar Pharmaceuticals 01-Jan-2010 Merger/Acquisition Media and Information Services (B2B)
To view this company’s complete investment and acquisition history, request access »

Vertex Pharmaceuticals Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 0000000000 07-Sep-2016 00000 00000 00 00000 Completed
  • 2 buyers
Altus Pharmaceuticals 06-Mar-2007 PIPE 0000 Completed
  • 3 buyers
To view this company’s complete exits history, request access »

Vertex Pharmaceuticals Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Vertex Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Vertex Pharmaceuticals Executive Team (22)

Name Title Board
Seat
Contact
Info
Jeffrey Leiden Ph.D Chairman, President and Chief Executive Officer
Ian Smith Executive Vice President, Chief Operating Officer and Chief Financial Officer
Michael Parini JD Executive Vice President & Chief Legal and Administrative Officer
David Bean Senior Vice President, Finance & CIO
David Altshuler Ph.D Executive Vice President, Global Research, Chief Scientific Officer and Board Member

8 Former Executives

You’re viewing 5 of 22 executives. Get the full list »

Vertex Pharmaceuticals Board Members (9)

Name Representing Role Since Contact
Info
Elaine Ullian Self Board Member 000 0000
Joshua Boger Ph.D Vertex Pharmaceuticals Co-Founder, Board Member & Chairman of Science and Technology Committee 000 0000
Margaret McGlynn Self Board Member 000 0000
Terrence Kearney Self Board Member & Chairman of Audit and Finance Committee 000 0000
Yuchun Lee Self Board Member 000 0000

4 Former Board Members

You’re viewing 5 of 9 board members. Get the full list »